Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2019 Oct 4;18(5):1197–1206.e7. doi: 10.1016/j.cgh.2019.09.033

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Kaplan-Meier curves comparing the cumulative incidence of HE development in patients who achieved SVR versus those who did not, among all patients or clinically-relevant subgroups.

a. ALL PATIENTS

b. ACCORDING TO ANTIVIRALREGIMEN

c. ACCORDING TO PRESENCE/ABSENCE OF CIRRHOSIS

DAA = direct acting antivirals, IFN = interferon, SVR = sustained virologic response